China News Service, Guangzhou, October 9th (Cai Minjie) "Although advanced breast cancer is currently difficult to cure, it can help advanced patients relieve their clinical symptoms by optimizing the treatment model, improving the accessibility of innovative drugs and the fairness of medical insurance. To improve the quality of life and further extend the survival time of patients." Wang Shusen, chief expert of breast cancer single disease at Sun Yat-sen University Cancer Hospital, said at a popular science education event for advanced breast cancer held in Guangzhou recently that the cure rate of early breast cancer exceeds 90%, and early screening is advocated. Early detection, early prevention and early treatment, and treatment of advanced breast cancer can improve the quality of life.
Every October is the "International Breast Cancer Awareness Month", which is established to raise people's awareness and awareness of breast cancer, early prevention, early detection, and early treatment.
In the above-mentioned advanced breast cancer science education activities, more than 20 first-line breast cancer experts from Guangdong Province jointly discussed the development of advanced breast cancer treatment strategies and the ways to prolong the long-term survival of patients.
According to statistics, there were about 304,000 new cases of breast cancer among Chinese women in 2015.
The report "The Status and Trends of Cancer in China in 2017" released by the National Cancer Center shows that the incidence of breast cancer ranks first among female malignant tumors.
The incidence of breast cancer in China is increasing rapidly at an annual rate of 3% to 4%.
"In breast cancer, we will emphasize classification and treatment. We divide breast cancer into different molecular types, and treat different types individually and differentiatedly. Among them, HR+ and HER2- are the most common types of breast cancer. Type." Wang Shusen said that in general this kind of common breast cancer, the current treatment effect has also made some progress, but there are still a considerable part of HER2-, HR+ breast cancer will eventually relapse or metastasis.
"In the past few decades, endocrine therapy has been the most important systemic treatment for the above-mentioned common types of breast cancer." Wang Shusen said that early ovariectomy can treat this type of breast cancer. With the discovery of hormone receptors, the medical community has realized This type of breast cancer is dependent on hormones, so anti-estrogen therapy has gradually become the most important systemic treatment for this type of breast cancer.
In the past ten years, from surgical treatment, chemotherapy, endocrine therapy to today’s targeted therapy, various treatments for advanced breast cancer have continued to change. In particular, the optimization of treatment strategies from “single” to “combined” has brought advanced breasts in the Mainland. Changes in the pattern of cancer treatment and changes in management models have enabled patients to continue to benefit from combined therapy, and their survival period has been greatly extended, making breast cancer a curable and controllable chronic disease like hypertension and diabetes.
"Some patients think that they will not be treated when they enter the advanced stage, or they hold the view that it is not good if the tumor does not disappear. This is wrong." Zhang Ying, deputy director of the Cancer Center of the Affiliated Hospital of Guangdong Medical University, said, the treatment of advanced breast cancer The principle is to improve the benefits of patients' survival. Clinically, the concept of managing advanced breast cancer as a "chronic disease" has gradually been accepted. Through various drug treatments, patients can "survive with the tumor" and prolong life.
The continuous innovation of drugs and the optimization of treatment strategies have brought possibilities for the long-term survival of advanced breast cancer, and the availability of treatment drugs needs to be improved.
In recent years, the reform and innovation of medical insurance in the field of anti-cancer and other measures have improved the protection of cancer patients.
Many breast cancer patients think that the cost of disease treatment is high, and thus give up treatment.
Zhang Ying said that in the face of expensive but life-saving targeted drugs, patients' demands cannot be avoided. On the one hand, medical insurance is required to increase subsidies, and on the other hand, commercial insurance is needed as a supplement.
Wang Shusen said that medical insurance reimbursement seems to be an act of reducing the burden of disease, but in fact it will soon be fed back into clinical treatment and research.
The introduction of new targeted drugs with clear curative effects into medical insurance can not only reduce the burden on patients, but also improve patients' compliance with treatment, thereby improving the quality of life and survival rate of cancer patients.
(Finish)